Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn’s Disease

Simona Barni1, Mattia Giovannini1*, Giulia Liccioli1, Lucrezia Sarti1, Anna Gissi2, Paolo Lionetti2 and Francesca Mori1

1 Allergy Unit, Department of Pediatrics, Meyer Children’s University Hospital, Florence, Italy, 2 Gastroenterology and Nutrition Unit, Meyer Children’s University Hospital, Florence, Italy

Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that is often associated with autoimmune or autoinflammatory conditions. Omalizumab is recommended in the treatment of refractory CSU in patients over 12 years of age who do not respond to four standard doses of antihistamines. Omalizumab blocks the mast cells’ degranulation, thus interrupting the resulting inflammatory cascade driven by T-helper 2 (Th2) cytokines. The efficacy of omalizumab in controlling CSU and possible associated diseases has been studied in few patients so far. In particular, some case reports describe adults with CSU and concomitant inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) or ulcerative colitis (UC). Although the treatment of CD with anti-tumor necrosis factors-α (TNF-α) seems to be effective in controlling CSU, no cases of the utility of omalizumab in patients with both conditions have been described so far. At the moment, there is no evidence that the pathogenetic mechanisms underlying CD are linked to the same pathways that are inhibited by omalizumab for the treatment of CSU. We present the first pediatric case of refractory CSU and CD in which omalizumab led to CSU remission, even if the follow-up period was limited. In conclusion, our experience shows how CSU could be associated with CD and successfully treated with the monoclonal anti-IgE antibody in a patient on immunosuppressive therapy. However, more data is needed from a larger population.

Keywords: anti-IgE monoclonal antibody, chronic spontaneous urticaria, inflammatory bowel diseases, Crohn’s disease, omalizumab, adolescent

INTRODUCTION

Omalizumab is a recombinant monoclonal antibody (mAb)—direct against the Fcε portion of the immunoglobulin (Ig)E antibodies—that blocks interaction with the high-affinity receptors (FccRI) expressed on the surface of target cells such as basophils and mast cells and that, consequently, blocks their release of several mediators (1).
Omalizumab acts mainly on a T-helper 2 (Th2) inflammation with a prominent role on mastocytes by inhibiting their degranulation and interrupting the resulting inflammatory cascade driven by Th2 cytokines (2). The efficacy of omalizumab has been proven in several diseases with a high level of evidence (i.e., allergic asthma, chronic urticaria, allergic rhinitis), medium level of evidence (i.e., nasal polyposis, facilitation of oral food allergen immunotherapy, facilitation of subcutaneous immunotherapy to aeroallergens, non-allergic asthma, allergic bronchopulmonary aspergillosis), and low level of evidence (i.e., mast cell activation syndrome, idiopathic anaphylaxis, atopic dermatitis, eosinophilic esophagitis, aspirin-exacerbated respiratory disease, asthma-chronic obstructive pulmonary disease overlap) (3).

In particular, the utility and safety of omalizumab in the treatment of severe allergic asthma has been known for many years. Indeed, it was approved by the United States Food and Drug Administration (FDA) in 2003, and 2 years later by the European Medicine Agency (EMA).

Moreover, the European Academy of Allergy and Clinical Immunology (EAACI), European Dermatology Forum (EDF), Global Allergy and Asthma European Network (GA2LEN), and World Allergy Organization (WAO) recommended the use of omalizumab in step three of the treatment for chronic spontaneous urticaria (CSU) in patients 12 years or older (3). CSU is defined by the daily appearance of wheals and/or angioedema, without an identified trigger, for a period lasting at least 6 weeks (3).

Autoimmunity seems to play a role of paramount importance in CSU, which is frequently associated with other autoimmune diseases, especially thyroiditis and celiac disease (4). Recently, few reports describe CSU associated with autoinflammatory gastrointestinal diseases, such as ulcerative colitis (UC) and Crohn’s disease (CD), especially in adult patients (5–8).

We describe the first pediatric case of a girl with CD who developed refractory CSU and required treatment with omalizumab, leading to CSU remission.

CASE REPORT

We present the case of a Caucasian girl who has been suffering from CD since she was 12 years old. The colonoscopy revealed linear millimetric ulcerations on slightly hyperemic mucosa in the terminal ileum; the ileocecal valve presented rounded ulceration on the proximal edge; the mucosa of the whole colon up to the rectum was normal in appearance. The histological exam showed that, at the level of the terminal ileum and ileo-cecal valve, architecture of villi was within normal limits without an increase in intraepithelial T lymphocytes with pseudo-atrophic aspects and erosions of the epithelial lining. In the lamina propria, an increase in the inflammatory component, partly in the form of hyperplastic follicular lymphoid aggregates, partly in the neutrophilic and eosinophilic component, involved in some points the glandular structures without creating cryptic abscesses. There were no giant cells or granulomas. The cecum, the ascending-transverse-descending colon, the sigma and rectum were of normal morphology. At 12 years old, she started therapy with azathioprine and mesalazine without any disease relapse. At 17 years of age, she began to present episodes of angioedema, which were, in the beginning, isolated and, after 6 months, associated with urticaria. The patient had not undergone any treatment change for CD in the previous 5 years. In January 2019, she was referred to our Allergy Unit as urticarial episodes occurred daily (Figure 1) and persistently for more than 6 weeks despite being treated with second-generation non-sedating H1-antihistamines (sgAH1) up to 2 fold the approved doses. On the physical examination, she presented diffuse wheals, especially on the trunk and legs but sparing the face, in the absence of angioedema or other relevant clinical manifestations, including articular or musculoskeletal ones. Moreover, no clinical features of urticarial vasculitis were detected, which allowed us to rule it out. A full diagnostic work-up for chronic urticaria was performed (Table 1). She underwent a gastroenterology visit with esophagogastroduodenoscopy and colonoscopy with retrograde ileoscopy, which ruled out a relapse of CD. Moreover, the fecal calprotectin and the erythrocyte sedimentation rate (ESR) were in the normal range (Table 1). Therefore, she was diagnosed with CSU and angioedema in a patient with CD in remission.

We suggested maintaining the dose of sgAH1 twice a day and monitoring the disease activity by filling out the seven-day Urticaria Activity Score weekly (UAS7) as recommended by the EAACI/GA2LEN/EDF/WAO guideline (9). According to our center’s clinical guidance and as recently explained in a
TABLE 1 | Laboratory workup.

| Parameters, unit of measure | January 2019 | February 2020 | Normal range |
|----------------------------|--------------|---------------|--------------|
| CBC:                       |              |               |              |
| - WBC, n/mm³                | 5.310        | 4.980         | 4,000–10,000 |
| - ESO, n/mm³                | 63.7         | 81.2          | 30–350       |
| AST, U/L                    | 14           | 16            | 1–31         |
| ALT, U/L                    | 10           | 9             | 1–31         |
| Creatinine, mg/dl           | 0.65         | 0.60          | 0.50–1.20    |
| CRP, mg/dl                  | 0.6          | 0.5           | 0–0.7        |
| ESR, mm/hr                  | 13           | 15            | 2–37         |
| Specific IgE to common airway (mites, molds, animal epithelia and grass, weed, birch, olive, cypress pollens) and common food allergens (milk, egg, wheat, cod, tomato, soy, peanut), KU | <0.10         | np            | <0.10         |
| HP-Ab, U/ml                 | 0.10         | np            | <0.30        |
| TSH, μIU/ml                 | 3.13         | 3.01          | 0.35–4.94    |
| fT₄, pg/ml                  | 8.8          | 8.5           | 6–12         |
| TG-Ab, IU/ml                | 1            | 1             | <4           |
| TPO-Ab, IU/ml               | 1            | 1             | <9           |
| iTG-IgA, U/ml               | 0.4          | 1             | <7           |
| ANA                          | neg          | neg           | <1:80        |
| C3, mg/dl                   | 80           | np            | 66–185       |
| C4, mg/dl                   | 35           | np            | 15–52        |
| C1-INH quantative, g/l      | 0.22         | np            | 0.15–0.33    |
| C1-INH functional, %        | 100          | np            | 70–100       |
| Fecal calprotectin, μg/g    | 30           | 20            | <70          |

ANA, antinuclear antibodies; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C-reactive protein; CBC, complete blood count; C1-INH, C1 esterase inhibitor; CRP, C-reactive protein; EOS, eosinophils; ESR, erythrocytes sedimentation rate; fT₄, free-thyroxine; HP-Ab, Helicobacter pylori-antibodies; IgE, Immunoglobulin E; neg, negative; np, not performed; TG-Ab, thyroglobulin-antibodies; TPO-antibodies, thyroid peroxidase-antibodies; TSH, thyroid-stimulating hormone; iTG-IgA, transglutaminase-Immunoglobulin A-antibodies; WBC, white blood cell.

published article by Sarti et al., we adjusted the dose of the sgAH1 therapy based on the patient’s UAS7. Specifically, if the UAS7 was higher than 15 for at least 2 weeks, a step-up in therapy was performed. If it was 1–15, the sgAH1 dose was maintained. Finally, if it was 0 for at least 2 weeks, a step-down in therapy was performed (10). After 4 weeks, the patient was evaluated again through telemedicine; due to the low disease control, we suggested increasing the sgAH1 dose to three times a day (Figure 2). Taking into account the low control of urticaria despite the sgAH1 treatment at threefold, the approved doses and the occurrence of somnolence as a side effect of antihistamines at high doses, in June 2019, we started treatment with subcutaneous omalizumab (300 mg) every 4 weeks (Figure 1). The patient continued taking sgAH1 three times a day for the first two months of treatment with the monoclonal antibody. As her UAS7 progressively improved, the sgAH1 dose was tapered to two times a day and to once a day in September 2019 (Figure 2). After the sixth injection (November 2019), omalizumab was stopped for two months according to the therapeutic schedule approved in Italy. The patient continued to take only one dose of cetirizine until February 2020, when a relapse of urticaria’s and angioedema’s clinical manifestations occurred. For this reason, she was given a twofold increase in the standard dosage of her sgAH1 treatment. Also, to exclude a reactivation of CD, she underwent new tests (Table 1), which gave normal results. Because of the poor management of urticaria, sgAH1 was prescribed three times a day for a short period of time. Because of the poor tolerance to the latter therapy, in May 2020, we started the second cycle of treatment with subcutaneous omalizumab (300 mg) every 4 weeks (Figure 2). Through telemedicine, we decided to progressively reduce sgAH1 to twice a day and finally once a day from September 2020. In October 2020, she underwent the last omalizumab injection. From August to October 2020, the registered UAS7 was 0 (Figure 2). After one month from the last omalizumab injection, the urticaria and angioedema were under control with sgAH1 once a day, and UAS7 was still 0. Moreover, the patient received 12 injections of omalizumab without reporting any side effects.

**DISCUSSION**

In this case report, we highlighted the efficacy and safety of omalizumab in an adolescent with refractory CSU and CD in remission on immunosuppressive therapy. The use of monoclonal anti-IgE therapy in the immunosuppressed host is limited to a few case reports, including adult patients with the hyper-IgE syndrome (HIES) (11) and HIV infection (12) and an adolescent with a common variable immunodeficiency (CVI) (13). In particular, Bard et al. (11) reported the first case of a 26-year-old woman with HIES with severe recalcitrant eczematous dermatitis, which was successfully treated with high-dose monoclonal anti-IgE therapy. Moreover, Iemoli et al. (12) described a case of excellent tolerability and efficacy of omalizumab in the treatment of CSU in a 56-year-old HIV-positive man on antiretroviral therapy; in particular, the viral load remained undetectable, and the CD4+ T cell counts improved. Recently, Comberiati et al. (13) reported the first case of a 19-year-old female with CVID treated successfully in terms of efficacy and safety with omalizumab for CSU after a non-effective trial with intravenous immunoglobulin at immunomodulatory dosage. The remission of cutaneous symptoms was obtained after the first omalizumab injection and persisted after the 12-month follow-up period.

As already described, CSU is a mast cell-driven disease (14). Two groups of mast cell degranulating signals have been described so far: IgE auto-antibodies to auto-allergens (type I autoimmunity) and IgG or IgM autoantibodies targeting activating mast-cell receptors (type II autoimmunity) (15). These two types of autoimmune mechanisms of skin mast cell degranulation are considered to be relevant causes of CSU in most patients (15). Indeed, CSU has been associated with numerous autoimmune diseases, including inflammatory bowel diseases (IBDs) (4). However, very few case reports of CSU or angioedema in adult patients associated with IBDs have been described so far (5–8).

Farkas et al. and Freeman (5, 6) described two cases of hereditary angioedema (HAE) associated with CD: two males aged 35 and 29. The particularity of the latter clinical case (6) was that the patient’s mother suffered from the same diseases—HAE and CD—that are,
apparently, two unrelated conditions. Nevertheless, in this case, they appeared to be genetically linked. Mansueto et al. (16) reported the case of a 64-year-old man with CSU who presented signs and symptoms of subclinical CD, a manifestation that had never been previously described in these patients.

Currently, the action mechanism of omalizumab is not fully understood. It is known that it binds to free IgE, thus lowering free IgE levels and their receptors (17). In the literature, the use of omalizumab to treat CSU in patients with concomitant IBDs is limited to a few case reports. In particular, Witten et al. (18) described the successful use of omalizumab in a 23-year-old male with triple immune/autoinflammatory disease: CSU and angioedema associated with CD and familial Mediterranean fever (FMF). Grieco et al. (19) reported the case of a 49-year-old woman with UC who was under mesalazine treatment. She had autoimmune thyroiditis, chronic hypereosinophilia and CSU plus Besnier’s prurigo treated with omalizumab with the resolution of urticaria and improvement of cutaneous clinical manifestations of prurigo.

The CSU and CD have a strong autoimmune involvement with an increase of proinflammatory cytokines (20). One common thread in the pathophysiology of both diseases is the imbalance in cytokine levels, in particular for IL-17 and TNF-α (21–23). Habal et al. (24) described the first case of CSU with angioedema coexistent with CD that was successfully treated with anti-TNF-α agents. Whether the CSU was cured due to the remission of the CD or because the TNF-α was a common cytokine in the pathogenetic pathway of the two diseases is difficult to understand. The authors hypothesized that given the similarity of cytokine derangements in CSU and CD, therapies that target the TNF-α could be effective in both conditions (24). In support of this hypothesis, cases of patients with refractory CSU, who were successfully treated with TNF-α inhibitors, are described in the literature (25, 26). Conversely, so far, no studies have concluded that anti-IgE therapy could improve both CSU and CD. Indeed, although CSU and CD are autoimmune diseases sharing the imbalance of some cytokines, when present in the same patient, they appear to be two concomitant diseases, and one is not the cause of the other.

In conclusion, even if the follow-up period of our case was limited and more data would be needed on more extensive populations, our experience shows how CSU could be associated with CD and successfully treated with monoclonal anti-IgE antibody even in a patient on immunosuppressive therapy.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

SB, MG, GL, and LS conceptualized the work. SB, MG, FM, AG, and PL drafted the manuscript. SB and FM performed the
investigations and critically revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

The research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The publication fee was financed by Novartis. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

**ACKNOWLEDGMENTS**

The authors want to thank Novartis for its support in relation to this work.

**REFERENCES**

1. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. *J Allergy Clin Immunol* (2005) 115(3):459–65. doi: 10.1016/j.jaci.2004.11.053

2. Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. *J Allergy Clin Immunol* (2015) 135(2):337–42.e2. doi: 10.1016/j.jaci.2014.04.036

3. Cardet JC, Casale TB. New insights into the utility of omalizumab. *J Allergy Clin Immunol* (2019) 143(3):923–6.e1. doi: 10.1016/j.jaci.2019.01.016

4. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review. *Autoimmun Rev* (2017) 16:1196–208. doi: 10.1016/j.autrev.2017.10.003

5. Farkas H, Gyeney L, Nemanszky E, Káldi G, Kukán F, Masszi I, et al. Case Report Coincidence Of Hereditary Angioedema (Hae) With Crohn’s Disease. *Immunol Investigations* (1999) 28(1):43–53. doi: 10.3109/0882013990922722

6. Freeman HJ. Hereditary angioedematous edema and familial Crohn’s disease. *Can J Gastroenterol* (2000) 14(4):337–9. doi: 10.1155/2000/828679

7. Naimeh LG, Muller BA. Chronic urticaria in a 17-year-old patient with a past history of bowel disease. *Ann Allergy Asthma Immunol* (2001) 86(5):511–6. doi: 10.1016/S1081-1206(01)82898-0

8. Liutu M, Kalimo K, Kalimo J, Kalimo H. Etiologic aspects of chronic urticaria. *Int J Dermatol* (1998) 37(7):515–9. doi: 10.1046/j.1365-4632.1998.00328.x

9. Zuberbier T, Ascher S, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Maurer M. Inflammatory effects of omalizumab in patients with chronic spontaneous urticaria. *J Allergy Clin Immunol* (2009) 123(2):321–2.e1. doi: 10.1016/j.jaci.2008.05.050

10. Mansuetu P, Carroccio A, Corsale S, Di Lorenzo G, Di Prima L, Pirrone G, et al. Chronic urticaria as a presenting symptom of Crohn’s disease. *BMJ Case Rep* (2009) 2009:bcr08.2008.0781. doi: 10.1136/bcr.08.2008.0781

11. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. *Allergy Eur J Allergy Clin Immunol* (2017) 72(4):519–33. doi: 10.1111/all.13083

12. Witten J, Siles R, Shen B, Yaqo Q. Triple Disease Combination: Familial Mediterranean Fever, Crohn’s Disease, and Chronic Idiopathic Urticaria with Angioedema. *Inflamm Bowel Dis* (2015) 22(3):E12–3. doi: 10.1097/MIB.0000000000000702

13. Comberiati P, Costagliola G, Carli N, Legitimo A, D’Agostino F. Case report: Omalizumab in Crohn’s disease. *Clin Immunol* (2015) 156(2):170–1. doi: 10.1016/j.clinim.2015.03.011

14. Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a patient with chronic spontaneous urticaria. *J Rheumatol* (2009) 36(1):184–6. doi: 10.3899/jrheum.08.09020

15. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn’s disease in adolescents with common variable immunodeficiency. *J Pediatr Gastroenterol Nutr* (2013) 56(6):812–5. doi: 10.1097/MJP.0b013e3182968f9d

16. Habal F, Huang V. Angioedema associated with Crohn’s disease: Response to biologics. *World J Gastroenterol* (2012) 18(34):4784–80. doi: 10.3748/wjg.v18.i34.4787

17. Perry-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn’s disease: beyond antagonists of tumour necrosis factor. *Lancet* (2008) 372(9632):67–81. doi: 10.1016/S0140-6736(08)69095-2

18. Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. *Biol Direct* (2020) 15(1):1–10. doi: 10.1186/s13062-020-00280-5

19. dos Santos JC, Azor MH, Nojima Y, Lourenço FD, Prearo E, Maruta CW, et al. Increased circulating proinflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. *Int Immunopharmacol* (2008) 8(10):1433–40. doi: 10.1016/j.intimp.2008.05.016

20. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* (2011) 140(6):1756–67.e1. doi: 10.1053/j.gastro.2011.02.016

21. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn’s disease beyond antagonists of tumour necrosis factor. *Lancet* (2008) 372(9632):67–81. doi: 10.1016/S0140-6736(08)69095-2

22. Habal F, Huang V. Angioedema associated with Crohn’s disease: Response to biologics. *World J Gastroenterol* (2012) 18(34):4784–80. doi: 10.3748/wjg.v18.i34.4787

23. Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a patient with chronic spontaneous urticaria. *J Rheumatol* (2009) 36(1):184–6. doi: 10.3899/jrheum.08.09020

24. Habal F, Huang V. Angioedema associated with Crohn’s disease: Response to biologics. *World J Gastroenterol* (2012) 18(34):4784–80. doi: 10.3748/wjg.v18.i34.4787

25. Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. *Biol Direct* (2020) 15(1):1–10. doi: 10.1186/s13062-020-00280-5

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Barni, Giovannini, Liciolli, Sarti, Gissi, Lionetti and Mori. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.